These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27488683)

  • 1. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplicity considerations in subgroup analysis.
    Dmitrienko A; Millen B; Lipkovich I
    Stat Med; 2017 Dec; 36(28):4446-4454. PubMed ID: 28762525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
    Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
    J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers for treatment selection: statistical considerations.
    Chen JJ; Lu TP; Chen YC; Lin WJ
    Biomark Med; 2015; 9(11):1121-35. PubMed ID: 26507127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies.
    Fu H; Zhou J; Faries DE
    Stat Med; 2016 Aug; 35(19):3285-302. PubMed ID: 26892174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation-based adjustment after exploratory biomarker subgroup selection in phase II.
    Götte H; Kirchner M; Sailer MO; Kieser M
    Stat Med; 2017 Jul; 36(15):2378-2390. PubMed ID: 28436046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-Driven Subgroup Identification in Confirmatory Clinical Trials.
    Bunouf P; Groc M; Dmitrienko A; Lipkovich I
    Ther Innov Regul Sci; 2022 Jan; 56(1):65-75. PubMed ID: 34327673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient subgroup identification for clinical drug development.
    Huang X; Sun Y; Trow P; Chatterjee S; Chakravartty A; Tian L; Devanarayan V
    Stat Med; 2017 Apr; 36(9):1414-1428. PubMed ID: 28147447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.
    De Gruttola VG; Clax P; DeMets DL; Downing GJ; Ellenberg SS; Friedman L; Gail MH; Prentice R; Wittes J; Zeger SL
    Control Clin Trials; 2001 Oct; 22(5):485-502. PubMed ID: 11578783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES.
    Lipkovich I; Dmitrienko A
    J Biopharm Stat; 2014; 24(1):130-53. PubMed ID: 24392982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
    Alosh M; Huque MF; Bretz F; D'Agostino RB
    Stat Med; 2017 Apr; 36(8):1334-1360. PubMed ID: 27891631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.
    Schnell PM; Müller P; Tang Q; Carlin BP
    Clin Trials; 2018 Feb; 15(1):75-86. PubMed ID: 29035083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biostatistic tools in pharmacogenomics--advances, challenges, potential.
    Sato Y; Laird NM; Yoshida T
    Curr Pharm Des; 2010; 16(20):2232-40. PubMed ID: 20459388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjusting for misclassification in a stratified biomarker clinical trial.
    Liu C; Liu A; Hu J; Yuan V; Halabi S
    Stat Med; 2014 Aug; 33(18):3100-13. PubMed ID: 24733510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.